ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Boehringer acquires cancer vaccine firm AMAL Therapeutics

by Lisa M. Jarvis
July 19, 2019 | APPEARED IN VOLUME 97, ISSUE 29

Aiming to expand its cancer drug portfolio, Boehringer Ingelheim is acquiring the Swiss biotech firm AMAL Therapeutics in a deal worth up to $365 million. The purchase gives Boehringer a cancer vaccine, ATP128, slated to begin human studies later this month in people with late-stage colon cancer. Boehringer says AMAL’s vaccine technology dovetails with its goal of developing a range of treatments that target “cold” tumors—ones that don’t respond to current cancer immunotherapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment